The Application of Clinical Genetics (Apr 2021)
Genetic Predictors of Mortality in Patients with Multiple Myeloma
Abstract
Hamza Hassan,1 Raphael Szalat1,2 1Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, MA, USA; 2Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USACorrespondence: Raphael SzalatDepartment of Hematology and Oncology, FGH Building, One Boston Medical Center Pl, Boston, MA, 02118, USATel +1 617 638 6428Email [email protected]: Multiple myeloma (MM) is a heterogeneous disease featured by clonal plasma cell proliferation and genomic instability. The advent of next-generation sequencing allowed unraveling the complex genomic landscape of the disease. Several recurrent genomic aberrations including immunoglobulin genes translocations, copy number abnormalities, complex chromosomal events, transcriptomic and epigenomic deregulation, and mutations define various molecular subgroups with distinct outcomes. In this review, we describe the recurrent genomic events identified in MM impacting patients’ outcome and survival. These genomic aberrations constitute new markers that could be incorporated into a prognostication model to eventually guide therapy at every stage of the disease.Keywords: multiple myeloma, genomics, aneuploidy, copy number abnormalities, structural variants, translocations, mutations, overall survival
